Bliss GVS Pharma Limited
NSE: BLISSGVS BSE: BLISSGVS
NSE
136.48
-3.06 (-2.19%)
Prev Close
139.54
Open Price
138.9
Volume
365,062
Today Low / High
135.85 / 139.7
52 WK Low / High
101.01 / 185.5
Range
130 - 143
BSE
136.50
-3.05 (-2.19%)
Prev Close
139.55
Open Price
138.2
Volume
41,865
Today Low / High
135.75 / 139.65
52 WK Low / High
101 / 184.95
Range
130 - 143
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 136.48 (target range: 130 - 143), reflecting a change of -3.06 (-2.19292%). On the BSE, it is listed at 136.5 (target range: 130 - 143), showing a change of -3.05 (-2.1856%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
06 Jun
138.90
-1.74%
05 Jun
132.88
5.01%
04 Jun
133.80
-0.63%
03 Jun
133.50
-0.25%
02 Jun
130.95
2.13%
30 May
133.45
-1.87%
29 May
133.00
0.41%
28 May
130.20
1.61%
27 May
125.90
3.51%
26 May
126.46
-0.68%
23 May
127.00
-0.43%
22 May
121.50
3.84%
21 May
122.25
-0.58%
20 May
124.90
-2.48%
19 May
119.00
3.97%
16 May
120.11
0.23%
15 May
119.05
1.15%
14 May
118.60
0.28%
13 May
118.00
0.47%
12 May
117.01
1.50%
09 May
111.00
0.76%
Bliss GVS Pharma Limited Graph
Bliss GVS Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bliss GVS Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 136.48, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 136.50 | 137.87 | 124.08 - 151.65 |
| 139.23 | 111.38 - 167.08 | ||
| 140.60 | 98.42 - 182.77 | ||
| Bearish Scenario | 136.50 | 135.14 | 121.62 - 148.65 |
| 133.77 | 107.02 - 160.52 | ||
| 132.41 | 92.68 - 172.13 |
Overview of Bliss GVS Pharma Limited
ISIN
INE416D01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
433,596
Market Cap
14,380,897,600
Last Dividend
0.5
Official Website
IPO Date
2010-07-26
DCF Diff
66.01
DCF
70
Financial Ratios Every Investor Needs
Stock Dividend of BLISSGVS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-24 | July 24, 25 | 0.5 | 0.5 | 2025-07-24 | 2025-08-30 | |
| 2024-07-18 | July 18, 24 | 0.5 | 0.5 | 2024-07-18 | 2024-08-24 | |
| 2023-07-12 | July 12, 23 | 0.5 | 0.5 | 2023-07-12 | 2023-08-18 | |
| 2022-06-20 | June 20, 22 | 0.5 | 0.5 | 2022-06-21 | 2022-07-28 | |
| 2021-09-13 | September 13, 21 | 0.5 | 0.5 | 2021-09-14 | 2021-10-20 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 765.91 Cr | 516.48 Cr | 249.43 Cr | 0.3257 | 15.23 Cr | 8.41 Cr | 123.10 Cr | 75.45 Cr | 7.23 | 148.81 Cr | 0.0985 |
| 2023-03-31 | 751.59 Cr | 401.32 Cr | 350.26 Cr | 0.4660 | 21.79 Cr | 7.28 Cr | 98.65 Cr | 70.86 Cr | 6.83 | 135.11 Cr | 0.0943 |
| 2022-03-31 | 737.93 Cr | 390.98 Cr | 346.95 Cr | 0.4702 | 21.38 Cr | 8.88 Cr | 101.32 Cr | 15.04 Cr | 1.46 | 76.24 Cr | 0.0204 |
| 2021-03-31 | 568.69 Cr | 328.91 Cr | 239.78 Cr | 0.4216 | 10.40 Cr | 6.97 Cr | 89.45 Cr | 68.49 Cr | 6.64 | 126.87 Cr | 0.1204 |
| 2020-03-31 | 681.91 Cr | 439.97 Cr | 241.94 Cr | 0.3548 | 7.69 Cr | 6.04 Cr | 111.15 Cr | 97.27 Cr | 9.43 | 149.12 Cr | 0.1426 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 23.14 Cr | 1,213.87 Cr | 210.89 Cr | 967.1933 Cr | 99.84 Cr | 76.70 Cr | 118.45 Cr | 369.38 Cr | 6.92 Cr | 0.06 Cr | 8.02 Cr | 159.8210 Cr |
| 2023-03-31 | 24.96 Cr | 1,156.85 Cr | 239.43 Cr | 883.8969 Cr | 101.90 Cr | 76.94 Cr | 103.06 Cr | 372.91 Cr | 42.06 Cr | 0.07 Cr | 56.86 Cr | 193.2590 Cr |
| 2022-03-31 | 21.92 Cr | 1,108.75 Cr | 262.28 Cr | 818.7017 Cr | 109.39 Cr | 87.48 Cr | 123.94 Cr | 294.82 Cr | 57.71 Cr | 0.09 Cr | 3.68 Cr | 233.0862 Cr |
| 2021-03-31 | 12.63 Cr | 1,076.79 Cr | 248.88 Cr | 808.2534 Cr | 121.90 Cr | 109.26 Cr | 98.93 Cr | 227.82 Cr | 41.79 Cr | 0.10 Cr | 62.01 Cr | 203.6358 Cr |
| 2020-03-31 | 15.09 Cr | 1,029.02 Cr | 278.65 Cr | 735.6130 Cr | 126.13 Cr | 111.03 Cr | 74.14 Cr | 232.62 Cr | 51.46 Cr | 0.11 Cr | 1.02 Cr | 232.1844 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 152.4486 Cr | -132.8218 Cr | -20.8930 Cr | 124.1193 Cr | -1.4163 Cr | 23.5906 Cr | -28.3293 Cr | 75.4541 Cr | -8.8958 Cr | -5.3949 Cr | -22.4218 Cr |
| 2023-03-31 | 34.3135 Cr | -7.7509 Cr | -24.9385 Cr | -59.4855 Cr | 3.0198 Cr | 25.0069 Cr | -93.7990 Cr | 106.0716 Cr | -13.8732 Cr | -5.4372 Cr | 15.0032 Cr |
| 2022-03-31 | 135.4806 Cr | -92.9751 Cr | -23.7301 Cr | 61.4775 Cr | 8.8526 Cr | 21.9871 Cr | -74.0031 Cr | 127.7598 Cr | -15.6057 Cr | -5.3265 Cr | -29.0968 Cr |
| 2021-03-31 | 63.9694 Cr | -46.9910 Cr | -20.7980 Cr | 54.8452 Cr | -2.2050 Cr | 13.1345 Cr | -9.1242 Cr | 104.1270 Cr | -8.9288 Cr | -5.5495 Cr | -26.8011 Cr |
| 2020-03-31 | 45.2796 Cr | -48.9489 Cr | -3.8269 Cr | -15.0353 Cr | 0.3032 Cr | 15.3425 Cr | -60.3149 Cr | 128.9651 Cr | 11.0777 Cr | -12.5000 Cr | 0.8055 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 210.42 Cr | 114.20 Cr | 96.22 Cr | 0.4573 | 22.24 Cr | 23.80 Cr | 2.27 | 45.05 Cr | 0.1131 |
| 2024-09-30 | 217.68 Cr | 149.41 Cr | 68.27 Cr | 0.3136 | 34.50 Cr | 24.26 Cr | 2.31 | 46.51 Cr | 0.1115 |
| 2024-06-30 | 183.64 Cr | 118.53 Cr | 65.12 Cr | 0.3546 | 27.48 Cr | 20.70 Cr | 1.97 | 38.45 Cr | 0.1127 |
| 2024-03-31 | 198.13 Cr | 126.83 Cr | 71.30 Cr | 0.3599 | 21.50 Cr | -9.15 Cr | -0.88 | 3.40 Cr | -0.0462 |
| 2023-12-31 | 200.72 Cr | 102.49 Cr | 98.23 Cr | 0.4894 | 42.16 Cr | 27.61 Cr | 2.64 | 49.12 Cr | 0.1376 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 33.11 Cr | 199.92 Cr | 233.03 Cr | 0.00 Cr | 131.41 Cr | 851.41 Cr | 379.18 Cr | 1,282.51 Cr | 234.46 Cr |
| 2024-06-30 | -140.37 Cr | 280.73 Cr | 140.37 Cr | 0.00 Cr | 0.00 Cr | 140.37 Cr | 0.00 Cr | 0.00 Cr | -1,002.98 Cr |
| 2024-03-31 | 215.62 Cr | 0.56 Cr | 216.17 Cr | 414.93 Cr | 118.45 Cr | 811.62 Cr | 369.38 Cr | 1,213.87 Cr | 210.89 Cr |
| 2023-12-31 | -162.93 Cr | 325.86 Cr | 162.93 Cr | 0.00 Cr | 0.00 Cr | 162.93 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 42.18 Cr | 128.49 Cr | 170.67 Cr | 378.06 Cr | 125.21 Cr | 746.52 Cr | 372.80 Cr | 1,197.12 Cr | 234.33 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 20.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -9.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 27.61 Cr | 13.91 Cr | 0.00 Cr | 0.00 Cr | 13.91 Cr | 175.87 Cr | 161.96 Cr | 0.00 Cr | 13.91 Cr |
| 2023-09-30 | 42.31 Cr | 13.83 Cr | 0.00 Cr | 0.00 Cr | 13.83 Cr | 161.96 Cr | 148.13 Cr | 0.00 Cr | 13.83 Cr |
| 2023-06-30 | 14.69 Cr | 1.15 Cr | 0.00 Cr | 0.00 Cr | -63.39 Cr | 1.15 Cr | 64.54 Cr | 0.00 Cr | 1.15 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,679.20 | ₹4,028,870,976,000.00 | ₹2,500,031.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,544.50 | ₹1,737,361,870,500.00 | ₹361,018.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,320.90 | ₹1,100,458,988,118.00 | ₹2,158,463.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,154.30 | ₹1,067,557,063,500.00 | ₹86,576.00 |
| Mankind Pharma Limited | MANKIND | ₹2,352.40 | ₹970,767,378,020.00 | ₹353,197.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹960.15 | ₹966,131,734,500.00 | ₹810,089.00 |
| Lupin Limited | LUPIN | ₹1,999.60 | ₹913,207,322,000.00 | ₹1,289,535.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,161.10 | ₹674,369,202,200.00 | ₹392,642.00 |
| Alkem Laboratories Limited | ALKEM | ₹4,862.50 | ₹581,384,812,500.00 | ₹181,782.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,590.20 | ₹448,756,030,200.00 | ₹940,265.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹1,055.10 | ₹403,646,450,141.00 | ₹209,681.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,370.90 | ₹347,802,813,600.00 | ₹594,702.00 |
| Laurus Labs Limited | LAURUSLABS | ₹642.05 | ₹346,227,388,650.00 | ₹1,658,718.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,571.30 | ₹321,186,225,600.00 | ₹84,218.00 |
| Piramal Enterprises Limited | PEL | ₹1,173.70 | ₹266,051,968,600.00 | ₹1,087,297.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,702.30 | ₹265,322,180,300.00 | ₹62,791.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,790.00 | ₹244,750,000,000.00 | ₹123,199.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,505.40 | ₹244,595,886,600.00 | ₹803,276.00 |
| Eris Lifesciences Limited | ERIS | ₹1,638.30 | ₹223,111,885,500.00 | ₹55,563.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹987.60 | ₹194,125,618,800.00 | ₹40,498.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,140.00 | ₹181,580,340,000.00 | ₹116,733.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,030.00 | ₹167,173,597,000.00 | ₹539,376.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,093.30 | ₹159,115,291,610.00 | ₹64,315.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹858.30 | ₹153,730,113,000.00 | ₹354,578.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹529.95 | ₹128,536,192,800.00 | ₹485,798.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,560.50 | ₹92,300,963,700.00 | ₹8,096.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹914.45 | ₹89,424,888,505.00 | ₹310,698.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹909.25 | ₹82,409,528,235.00 | ₹242,116.00 |
| Strides Pharma Science Limited | STAR | ₹782.30 | ₹72,098,880,210.00 | ₹430,298.00 |
| FDC Limited | FDC | ₹429.20 | ₹69,878,052,000.00 | ₹308,089.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹165.55 | ₹53,724,617,100.00 | ₹2,347,837.00 |
| Innova Captab Limited | INNOVACAP | ₹889.10 | ₹50,878,685,263.00 | ₹72,505.00 |
| Suven Life Sciences Limited | SUVEN | ₹221.19 | ₹48,235,788,060.00 | ₹1,475,325.00 |
| Sequent Scientific Limited | SEQUENT | ₹187.85 | ₹47,019,230,700.00 | ₹442,806.00 |
| Hikal Limited | HIKAL | ₹372.35 | ₹45,911,127,350.00 | ₹154,610.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹462.15 | ₹42,180,430,500.00 | ₹112,178.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹592.90 | ₹41,743,598,820.00 | ₹18,878.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹368.10 | ₹36,912,331,800.00 | ₹50,918.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹718.15 | ₹36,423,921,665.00 | ₹149,821.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,141.70 | ₹35,421,576,300.00 | ₹12,390.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹64.12 | ₹35,134,810,480.00 | ₹2,840,731.00 |
| Alembic Limited | ALEMBICLTD | ₹112.07 | ₹28,777,558,628.00 | ₹591,652.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹88.74 | ₹26,047,585,980.00 | ₹1,118,303.00 |
| Indoco Remedies Limited | INDOCO | ₹275.10 | ₹25,377,397,290.00 | ₹25,198.00 |
Key Executives
Compliance Officer, Company Secretary & Nodal Officer
Ms. Aditi Himanshu Bhatt
Gender: female
Year Born:
Associate Vice President
Mr. Sourya Das
Gender: male
Year Born:
Executive & Whole Time Director
Ms. Shruti N. Vishal Rao
Gender: female
Year Born: 1985
Vice President of Technical Operations
Mr. Prashant Churi
Gender: male
Year Born:
Chief Financial Officer
Mr. Deepak B. Sawant
Gender: male
Year Born: 1980
Executive & Whole Time Director
Dr. Vibha Gagan Sharma
Gender: Not Specified
Year Born: 1983
MD & Director
Mr. Gagan Harsh Sharma
Gender: male
Year Born: 1983
FAQs about Bliss GVS Pharma Limited
Who is the CEO of the company?
The CEO is Mr. Gagan Harsh Sharma.
What is the current market price of the stock?
The current price is ₹136.48.
What is the 52-week price range?
The range is ₹101.01-185.5.
What is the market capitalization of the company?
The market capitalization is ₹1,438.09 crores.
What is the dividend yield?
The dividend yield is 0.37%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 24.01.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bliss GVS Pharma Limited (ISIN: INE416D01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,438.09 crores and an average daily volume of 433,596 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.5.